Navigation Links
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Date:12/9/2008

icine, Hematology/Neurology, and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and reported revenues in 2007 of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States. Genzyme(R), Campath(R) and MabCampath(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015  Echo Therapeutics, Inc. ... focused on non-invasive continuous glucose monitoring and associated ... and completely re-designed corporate website echotx.com . ... to Echo,s technology and enhances the quality and ... website better communicates to prospective customers and stakeholders ...
(Date:7/1/2015)... and FT LAUDERDALE, Florida , July 1, ... designer, developer, manufacturer and marketer of innovative medical devices for ... 13, 2015, it prevailed in a final opposition appeal hearing ... 1 341 482 - STENT HAVING HELICAL ELEMENTS (,482). The ... the EPO and has been upheld as a valid patent ...
(Date:7/1/2015)... July 1, 2015  Imprimis Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of proprietary compounded drug ... The Nasdaq stock market closing bell on Thursday, ... success of its Go Dropless™ campaign since its ... procedures are performed annually in the U.S. and ...
Breaking Medicine Technology:Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4
... Jan. 31, 2012 The U.S. Food and Drug ... in adult patients following surgical removal of CD117-positive gastrointestinal ... in overall patient survival when the drug is taken ... of treatment. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
... Jan. 31, 2012 Synteract, Inc., a ... its electronic data capture system SynCapture™, providing customers with ... study data to be captured into a single database ... web based, resulting in more seamless, flexible and cost ...
Cached Medicine Technology:FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer 2FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer 3Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System 2
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will partner ... Twin Cities on Saturday, August 1, at Spring Lake Park High School. , During ... than $1 million worth of goods and services including free food, health services, family ...
(Date:7/1/2015)... West Orange, NJ (PRWEB) , ... July 01, 2015 , ... Scoliosis is a disorder ... to the National Scoliosis Foundation, it affects 2 to 3 percent of the population, or ... ages, scoliosis most often develops in children between the ages of 10 and 15. Most ...
(Date:7/1/2015)... ... 2015 , ... A Priority Setting Partnership put in place ... they hope will guide future mesothelioma research. Surviving Mesothelioma has just posted an ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer the mesothelioma ...
(Date:7/1/2015)... , ... July 01, 2015 , ... B. E. Smith, ... to lead a national chief nursing officer recruitment for Capital Health ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... Research ... Examination Kit (Peek) smartphone app to test eyesight was just as accurate as those ... School of Hygiene and Tropical Medicine is responsible for the development of the test, ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3
... immune systemlead to the "hyperinflammation" characteristic of obesity-related glucose ... from the University of Cincinnati (UC). Cancer ... the cellular mechanisms behind glucose intolerance may provide a ... as well as insights into how aggressive cancers form. ...
... heated, magnetic nanoparticles targeted to cell membranes can ... behavior, according to a paper published by University ... The research could have broad application, potentially resulting ... proteins or cells in specific tissues, or improved ...
... ... Tilda Swinton as the latest famous faces to lend their support to Hear the ... the importance of hearing and the consequences of hearing loss. , , ... (PRWEB) July 6, 2010 -- ...
... LAKE CITY Severe trauma to the head and ... dramatically according to research released today from the University ... be published in the journal Neurosurgery , highlights ... helmet use, and greater efforts to train riders in ...
... ... keys to identifying goals and achieving success during challenging times? How ... and conviction? How does one rebound from the losing things held ... 12 secret keys that inspire readers to overcome feelings of confusion and ...
... ... larger office and more convenient location within the Boise medical community. Still serving ... proximity to one of the major medical centers in Boise. This new office ... to help patients get and stay healthy. , ...
Cached Medicine News:Health News:Fat cells play key role in development of type 2 diabetes 2Health News:With magnetic nanoparticles, scientists remotely control neurons and animal behavior 2Health News:More Big Names Line Up To Support Global Hearing Loss Awareness Initiative 2Health News:More Big Names Line Up To Support Global Hearing Loss Awareness Initiative 3Health News:Head and spine trauma from ATV accidents cost $3.24 billion annually 2Health News:Head and spine trauma from ATV accidents cost $3.24 billion annually 3Health News:New Book, "Driven by Destiny" by Dr. LaVerne Adams, Foreword by Rick Warren Reveals 12 Secret Keys to Transform the Future 2Health News:New Book, "Driven by Destiny" by Dr. LaVerne Adams, Foreword by Rick Warren Reveals 12 Secret Keys to Transform the Future 3Health News:Boise Acupuncture Clinic Grows into Larger Office 2
... switch which allows user to stop rotor before ... with stainless steel pin is virtually indestructible. Lid ... 6 microcentrifuge tubes at low to medium speed ... 6 inch x 6 inch footprint. Starts and ...
Inquire...
Inquire...
... meets or exceeds all the requirements set ... the Determination of Packed Cell Volume by ... U.S. and international standards and protocols., For ... 3411 or 3412 and you'll receive all ...
Medicine Products: